BREZTRI AEROSPHERE Drug Patent Profile

When do Breztri Aerosphere patents expire, and what generic alternatives are available?

Breztri Aerosphere is a drug marketed by Astrazeneca Ab and is included in one NDA. There are nine patents protecting this drug.

The generic ingredient in BREZTRI AEROSPHERE is budesonide; formoterol fumarate; glycopyrrolate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the budesonide; formoterol fumarate; glycopyrrolate profile page.

DrugPatentWatch^® Generic Entry Outlook for Breztri Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 27, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BREZTRI AEROSPHERE

US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BREZTRI AEROSPHERE
DailyMed Link:	BREZTRI AEROSPHERE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BREZTRI AEROSPHERE

Constraining patent/regulatory exclusivity:

NEW STRENGTH

NDA:

212122

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BREZTRI AEROSPHERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AstraZeneca	PHASE4
Dr. J. Alberto Neder	PHASE4
Jianxing He	N/A

See all BREZTRI AEROSPHERE clinical trials

Pharmacology for BREZTRI AEROSPHERE

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Cholinergic Muscarinic Antagonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for BREZTRI AEROSPHERE

BREZTRI AEROSPHERE is protected by sixteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW STRENGTH.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-002	Apr 27, 2026		RX	Yes	Yes			Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes			Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-002	Apr 27, 2026		RX	Yes	Yes			Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes			Y

International Patents for BREZTRI AEROSPHERE

When does loss-of-exclusivity occur for BREZTRI AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Netherlands

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BREZTRI AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	076621
Argentina	076806
Argentina	076807
Argentina	121758
Argentina	122477
Argentina	122478

Supplementary Protection Certificates for BREZTRI AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2435025	300995	Netherlands		PRODUCT NAME: COMBINATIE VAN GLYCOPYRRONIUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER GLYCOPYRRONIUYM BROMIDE, EN FORMOTEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER, IN HET BIJZONDER FORMOTEROL FUMARAAT DIHYDRAAT; REGISTRATION NO/DATE: EU/ 1/18/1339 20181220
2435025	PA2019014	Lithuania		PRODUCT NAME: GLIKOPIROLATO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) IR FORMOTEROLIO (ISKAITANT BET KOKIAS JO FARMACINIU POZIURIU PRIIMTINAS DRUSKAS, ESTERIUS, ENANTIOMERUS AR KITUS DARINIUS) DERINYS; REGISTRATION NO/DATE: EU/1/18/1339 20181218
2435025	122019000068	Germany		PRODUCT NAME: KOMBINATION VON GLYCOPYRROLAT, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON, UND FORMOTEROL, EINSCHLIESSLICH BELIEBIGER PHARMAZEUTISCH VERTRAEGLICHER SALZE, ESTER, ENANTIOMERE, ODER ANDERER DERIVATE DAVON; REGISTRATION NO/DATE: EU/1/18/1339 20181218
2435025	2019C/532	Belgium		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
2435025	LUC00124	Luxembourg		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220

BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol fumarate): Market Dynamics and Financial Trajectory

Last updated: July 24, 2026

Executive summary

• BREZTRI AEROSPHERE (AstraZeneca, budesonide/glycopyrrolate/formoterol) is a dominant US FDA-approved triple therapy for COPD. Post-launch demand has been supported by broad guideline alignment, payer acceptance for ICS/LABA/LAMA, and a large “switch” channel from dual and LAMA/LABA regimens.
• The commercial picture has shifted as generic ICS/LABA/LAMA combinations and mature competitor portfolios tightened price/mix. Still, BREZTRI’s momentum is sustained by high switching elasticity, inhaler-device familiarity, and ongoing class competition rather than direct “drop-in” substitutes.
• The next value inflection is linked to (1) US patent/exclusivity durability, (2) competitive intensity from other triple therapies and next-generation inhaled products, and (3) US payer contracting dynamics for high-value branded inhaled categories.

---

How does BREZTRI AEROSPHERE perform commercially in the US vs. competitors?

BREZTRI has functioned as the category’s leading branded triple therapy by combining an inhaled corticosteroid with dual long-acting bronchodilators in a single device. For payers and PBMs, the economic logic is typically framed around reducing exacerbations, improving symptom control, and limiting downstream healthcare costs.

Featured snippet answer: BREZTRI’s competitive strength in the US rests on being the best-selling branded triple therapy in a market where clinicians increasingly favor escalation to triple treatment for moderate-to-severe COPD and exacerbation-prone patients.

Key competitive pressure points

1. Other branded triple therapies
   • Trelegy Ellipta (GSK) is the nearest like-for-like comparator in guideline positioning (ICS/LABA/LAMA).
   • Other emerging or regionally strong triple options can compress market share at the margin, especially among commercially insured cohorts with aggressive formulary tiers.
2. Formulary and step-therapy
   • Payers often steer first-line to LABA/LAMA and reserve ICS-containing regimens for exacerbation history or higher symptom burden, creating a funnel that still benefits established triple therapies due to clinician “upgrade” pathways.
3. Device and adherence
   • BREZTRI’s delivery device and regimen simplicity support persistence, which can outlast efficacy-only comparisons where patient technique and refill behavior matter.

---

What is the financial trajectory for BREZTRI AEROSPHERE revenue over time?

BREZTRI’s revenue trajectory has followed a typical branded respiratory pattern: rapid early adoption, followed by steady growth as prescribers broadened use, then moderated growth as payers tightened budgets and competitor erosion increased.

Commercial lifecycle pattern (typical for branded COPD triple therapy)

• Launch-to-maturation: Strong uptake driven by COPD guideline support for escalation and brand education.
• Maturation phase: Growth becomes more dependent on net price, mix (exacerbation-prone and higher severity), persistence, and contracting rather than purely patient acquisition.
• Mid-cycle: Competitor launches and payer tiering move the category’s unit economics, forcing promotional and contracting adjustments.

What drives year-to-year revenue movement

• Unit volume growth vs. net price
• Exacerbation-driven conversion: Patients switching from dual bronchodilators to triple therapy
• Formulary stability: Whether BREZTRI stays on preferred tiers across major PBMs
• Channel mix: Retail vs. specialty pharmacy mix, Medicare Advantage penetration

(Note: No transaction-level revenue table or quarter-by-quarter figures are provided here because this brief is constrained to non-cited external performance metrics, and no reliable numeric dataset was included in the prompt.)

---

Which market dynamics are shifting COPD triple-therapy demand for BREZTRI?

Payer contracting and PBM behavior

• PBMs frequently use tiering and rebate structures to manage high-cost inhaled therapies. Over time, they attempt to improve value alignment with outcomes and step-edit compliance.
• As category competition increases, branded triple therapies experience more frequent contract renegotiations and higher rebate pressure, which dampens net revenue growth even when prescriptions hold up.

Clinical and guideline behavior

• COPD treatment algorithms increasingly emphasize escalation based on symptoms and exacerbation risk.
• Triple therapy has become an “upgrade destination” for patients failing dual bronchodilation or experiencing exacerbations on LAMA/LABA.
• Clinician adoption tends to be sticky once a stable regimen is found, which helps leaders like BREZTRI sustain volume even as unit net pricing declines.

R&D pipeline and competitor intensity

• Next-step competitive dynamics include device improvements, combination potency changes, and inhaler simplification across competitor portfolios.
• Even when new products are not perfect substitutes, they can alter prescriber preference, especially for treatment-naive patients or those with prior intolerance to specific components.

---

How many patents protect BREZTRI AEROSPHERE and what are the main expiration drivers?

BREZTRI’s long-term financial trajectory is strongly linked to the depth and layering of its US patent estate for:

• active ingredient composition and stereochemistry,
• formulation and delivery/device aspects (where applicable),
• methods of treatment (COPD severity/exacerbation subsets),
• and related combination claims.

Featured snippet answer: BREZTRI’s exclusivity durability is typically driven by a layered US patent estate plus regulatory exclusivities tied to the innovator approval, limiting generic substitution timelines even as payer pressure increases.

Key “expiration driver” categories investors track

• Compound and combination patents: block AB-rated generic entry
• Formulation and stability patents: block non-identical formulations
• Method-of-use patents: can constrain skinny-label or carve-out strategies
• Device and inhaler performance patents: can constrain generic device variants

---

When does BREZTRI AEROSPHERE lose exclusivity in the US?

Exclusivity loss timing in inhaled combinations depends on the interaction of:

• patent term end dates (including patent term adjustments and court-extended dates, if any),
• regulatory exclusivities tied to the New Chemical Entity/505(b)(1) pathways (where applicable),
• and any pediatric exclusivity or other legal extensions.

Featured snippet answer: BREZTRI’s US generic risk window opens only after the last blocking patent and/or exclusivity barrier is cleared, with Paragraph IV challenges typically accelerating the timeline through litigation and potential settlement.

(No explicit expiration dates are listed here because the prompt provides no patent-date dataset and this brief is not allowed to fabricate or imply dates.)

---

What generic entry risks exist for BREZTRI AEROSPHERE (Paragraph IV, settlements)?

For high-value branded inhaled triple therapies, generic entry risk usually manifests in two ways:

1. Paragraph IV filings seeking approval before full patent expiry by challenging listed patents’ validity or enforceability.
2. Type of resolution: dismissal, adverse judgment, or settlement-based entry with agreed launch dates (often coupled to agreed carve-outs or non-infringement redesigns).

Featured snippet answer: Generic entry risk depends on how many Orange Book-listed patents remain enforceable at the time of any Paragraph IV challenge and on whether any settlement provides an agreed “at-risk” launch date.

What to monitor

• Whether litigated patents are composition vs. formulation vs. method-of-use.
• Whether any settlement permits immediate generic launch or requires design changes.
• Whether the FDA approves under a label that preserves clinically relevant differentiation.

---

What patent litigation affects BREZTRI AEROSPHERE (case landscape and exposure)?

Triple-therapy leaders typically face:

• infringement suits after Paragraph IV notices,
• follow-on suits tied to design-around formulations,
• and potential appeals affecting entry calendars.

Featured snippet answer: Litigation exposure is highest when challengers target core blocking combination claims rather than minor formulation variants.

(No case captions, dockets, or dates are included because none were provided in the prompt.)

---

What is the Orange Book status of BREZTRI AEROSPHERE?

Orange Book status drives the practical launch calendar because FDA approval must respect each listed patent’s claim scope.

Featured snippet answer: BREZTRI’s Orange Book status determines which patents are “blocking” for AB-rated products and therefore which patents generic challengers must address in Paragraph IV challenges.

(No Orange Book patent list content is provided due to the absence of cited patent listings in the prompt.)

---

How does BREZTRI AEROSPHERE compare with Trelegy Ellipta and other triple therapies?

Head-to-head positioning

• Both BREZTRI and Trelegy deliver triple therapy for COPD. The practical competitive difference is less about clinical outcome headlines and more about:
  • formulary placement,
  • net price after rebates,
  • inhaler usability and patient preference,
  • and contracting dynamics across PBMs and health systems.

Market share implications

• When one product secures a preferred formulary tier at major PBMs, switching tends to follow the lowest total cost net of rebates and patient co-pays.
• In parallel, clinician experience and patient technique can sustain share even after unfavorable contracting changes.

---

What commercial levers do AstraZeneca typically use to defend BREZTRI’s position?

Inhaled respiratory leaders defend with:

• contracting discipline: rebate and access strategies to maintain preferred formulary placement,
• payer evidence packages: exacerbation reduction and disease-control value narratives,
• tender and health-system conversion: maintaining formulary presence in integrated delivery networks,
• support for adherence: pharmacy benefit design that reduces refill interruptions.

(No AstraZeneca-specific contracting terms are included, as none were supplied in the prompt.)

---

How do Medicare and managed-care dynamics affect BREZTRI net revenue?

• Medicare Part D formularies can influence the elderly COPD segment disproportionately because co-pay sensitivity and plan design affect adherence.
• Medicare Advantage plans increasingly negotiate on total cost and may use step therapy to steer patients into preferred inhaled regimens.
• Net revenue is therefore impacted by:
  • beneficiary uptake on preferred tiers,
  • utilization management rules,
  • and contract-specific rebate structures.

---

What are the investment and licensing implications of BREZTRI’s trajectory?

Licensing logic

Triple-therapy portfolios with broad IP coverage are often maintained internally because:

• device and formulation differentiation can reduce the attractiveness of licensing generic-like products,
• and because settlement economics depend on blocking patent strength.

Licensing decisions would typically focus on:

• geographic expansion,
• device manufacturing or packaging partnerships,
• and potential product line extensions rather than pure near-term generic replacement.

Investment logic

• For investors, the key proxy for risk is the probability-weighted path of:
  • exclusivity expiry,
  • litigation outcomes,
  • and net price erosion from competition.

---

Key Takeaways

• BREZTRI is positioned as a leading branded COPD triple therapy, with market dynamics driven by guideline-based escalation, payer tiering, and adherence/persistence.
• Financial trajectory typically transitions from volume-led growth to net-price/mix-led performance as competitor intensity rises.
• The biggest determinant of long-range revenue risk is the layered US patent and Orange Book exclusivity profile, which controls the timing and attractiveness of generic entry and potential settlement-driven launch calendars.
• Near-term performance is primarily a function of payer contracting stability and conversion from dual therapy, not just clinical differentiation.

---

FAQs

1. What PBM formulary trends most affect BREZTRI AEROSPHERE net pricing?
   Preferred tier placement, rebate structures, and step edits that govern ICS-containing triple therapy access.

2. How does COPD exacerbation risk profile influence BREZTRI prescribing and persistence?
   Patients with exacerbation history are more likely to be escalated and to remain on triple therapy once stable.

3. What launch timing risks matter most for generics entering BREZTRI?
   Whether generic filers can clear the most blocking combination and method-of-use patents, and whether settlements allow earlier launch.

4. Does device or inhaler technique change the competitive outlook for BREZTRI?
   Yes. Persistence and correct technique can affect real-world outcomes, supporting continued conversion and share retention.

5. How should investors model BREZTRI revenue after generic exclusivity ends?
   By combining patent expiry calendar risk with expected net price erosion and volume substitution speed driven by formulary acceptance and contracting.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. AstraZeneca. BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol fumarate) US prescribing information.
3. GSK. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) US prescribing information.
4. CMS / Medicare Part D. Prescription drug coverage and formulary/tiering framework documentation.